Paclitaxel plus doxorubicin in breast cancer: An italian experience

G. L. Frassineti, W. Zoli, L. Silvestro, P. Serra, C. Milandri, A. Tienghi, L. Gianni, A. Gentile, E. Salzano, D. Amadori

Research output: Contribution to journalArticle

Abstract

Based on preclinical data, phase I/II clinical trials were performed at Istituto Oncologico Romagnolo (IOR) Operative Units (Medical Oncology Departments of Forli, Rimini, and Ravenna, Italy) to determine the efficacy and toxicity of sequential administration of doxorubicin followed by paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) in the treatment of patients with advanced breast cancer that either had been previously untreated or that had relapsed after adjuvant therapy. In the phase I trial, 19 patients received bolus doxorubicin (50 mg/m2) followed after a 16-hour interval by paclitaxel (given at dose levels ranging from 130 to 250 mg/m2) by 3-hour infusion every 3 weeks, for a maximum of eight cycles. Paclitaxel doses were escalated in 30-mg/m2 increments if the maximum tolerated dose had not been reached in the previous dose level. Analysis of the 128 cycles assessable for toxicity demonstrated neutropenia (2 dose level (no grade 3 or 4 extramedullary toxicity). In the IOR phase II trial, 13 patients were treated with fixed doses of both drugs (doxorubicin 50 mg/m2 and paclitaxel 220 mg/m2). Grade 4 neutropenia occurred in 39 of the 95 cycles, but was complicated by fever in only eight cycles (8.4%); three cycles required granulocyte colony-stimulating factor support. Peripheral neurotoxicity was the most common extramedullary side effect noted. Overall clinical responses in the IOR trials included 10 complete responses (31.3%) and 15 partial responses (46.9%), with an objective response rate of 78.1%. Comparison of these results with those obtained from a phase I trial using the opposite drug sequence showed comparable overall response rates, but IOR's sequence was associated with a higher complete response rate, as well as less frequent and less severe nonhematologic toxicity.

Original languageEnglish
JournalSeminars in Oncology
Volume24
Issue number5 SUPPL. 17
Publication statusPublished - 1997

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Paclitaxel plus doxorubicin in breast cancer: An italian experience'. Together they form a unique fingerprint.

  • Cite this

    Frassineti, G. L., Zoli, W., Silvestro, L., Serra, P., Milandri, C., Tienghi, A., Gianni, L., Gentile, A., Salzano, E., & Amadori, D. (1997). Paclitaxel plus doxorubicin in breast cancer: An italian experience. Seminars in Oncology, 24(5 SUPPL. 17).